|
Patient demographics at baseline, according to systemic therapy prescribed as first treatment. |
||||||
| Methotrexate (N = 20) |
Cyclosporin (N = 10) |
Corticosteroids (N = 8) |
Combineda (N = 2) |
Retinoids (N = 1) |
All patients (N = 41) |
|
|
|
||||||
| Age (years) |
||||||
| Mean ± SD |
49 ± 10 |
43 ± 12 |
44 ± 11 |
47 ± 3 |
41 |
46 ± 11 |
| Range |
28–67 |
20–58 |
20–60 |
45–49 |
- |
20–67 |
| Gender (n (%)) |
||||||
| Male |
13 (65.0) |
5 (50.0) |
5 (62.5) |
1 (50.0) |
1 (100) |
25 (61.0) |
| Female |
7 (35.0) |
5 (50.0) |
3 (37.5) |
1 (50.0) |
0 |
16 (39.0) |
| Ethnicity (n (%)) |
||||||
| Caucasian |
15 (75.0) |
10 (100) |
8 (100) |
2 (100) |
1 (100) |
36 (87.8) |
| Asian |
2 (10.0) |
0 |
0 |
0 |
0 |
2 (4.9) |
| Other |
3 (15.0) |
0 |
0 |
0 |
0 |
3 (7.3) |
|
aCombined systemic corticosteroids plus methotrexate. | ||||||
Papp et al. BMC Dermatology 2006 6:9 doi:10.1186/1471-5945-6-9 |
||||||